Avadel Sues Jazz Over Narcolepsy-Drug-Patent Trade Secrets (2)

Avadel Pharmaceuticals PLC filed a lawsuit Thursday alleging that Jazz Pharmaceuticals PLC stole trade secrets and breached confidential disclosure agreements to acquire patents it’s wielding in a pending infringement dispute over Avadel’s proposed narcolepsy drug, a rival to Jazz’s Xyrem, source of 41% of Jazz’s 2021 sales.

The claims “arise out of Jazz’s continuing efforts to keep Avadel’s revolutionary once-nightly formulation of sodium oxybate,” called FT218, “for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy off the market,” Avadel said in a concurrent court filing in the U.S. District Court for the District of Delaware. ...